切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2011, Vol. 05 ›› Issue (03) : 252 -255. doi: 10.3877/cma.j.issn.1674-0793.2011.03.021

所属专题: 文献

讲座与综述

骨髓间充质干细胞联合基因治疗肝纤维化的研究进展
李明亮1, 邓美海1,()   
  1. 1. 510630 广州,中山大学附属第三医院肝胆外科
  • 收稿日期:2011-02-21 出版日期:2011-06-01
  • 通信作者: 邓美海
  • 基金资助:
    广东省自然科学基金(8151008901000112)

Progress in research of gene treatment for liver cirrhosis with bone marrow mesenchymal stem cells

Ming-liang LI1, Mei-hai DENG1,()   

  1. 1. Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2011-02-21 Published:2011-06-01
  • Corresponding author: Mei-hai DENG
  • About author:
    Corresponding author: DENG Mei-hai, Email:
引用本文:

李明亮, 邓美海. 骨髓间充质干细胞联合基因治疗肝纤维化的研究进展[J]. 中华普通外科学文献(电子版), 2011, 05(03): 252-255.

Ming-liang LI, Mei-hai DENG. Progress in research of gene treatment for liver cirrhosis with bone marrow mesenchymal stem cells[J]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(03): 252-255.

骨髓间充质干细胞治疗肝纤维化的关键在于促进肝细胞再生和抑制肝组织纤维化,但目前单独应用骨髓间充质干细胞治疗肝纤维化的效果不明显,由于骨髓间充质干细胞是外源基因的良好载体,相关研究发现,通过体内、体外将促进肝细胞再生和抑制肝组织纤维化的基因转染骨髓间充质干细胞,可以加强骨髓间充质干细胞治疗肝纤维化的效果,这为肝纤维化的治疗带来新的策略。

The key of treatment for liver cirrhosis with bone marrow mesenchymal stem cells lies in the promotion of hepatocellular regeneration and the inhibition of liver tissue fibrosis. However, it’s not effective to treat liver cirrhosis with bone marrow mesenchymal stem cells alone. For We know that bone marrow mesenchymal stem cells would be fine gene carriers, it can improve the result to treat liver cirrhosis with bone marrow mesenchymal stem cells carrying target gene, which be proved by related research via many experiment methods in-vitro and in-vivo. It brings a new treatment strategy for liver cirrhosis.

1
Mosca JD, Hendricks JK, Buyaner D, et al. Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res, 2000, 379 (Suppl): 71-90.
2
Lee K, Majumdar MK, Buyaner D, et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther, 2001, 3(6): 857-866.
3
Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science, 1999, 284(5417): 1168-1170.
4
Theise ND, Badve S, Saxena R, et al. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology, 2000, 31(1): 235-240.
5
Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology, 2000, 32(1): 11-16.
6
Crosby HA, Kelly DA, Strain AJ. Human hepatic stem-like cells isolated using c-kit or CD34 can differentiate into biliary epithelium. Gastroenterology, 2001, 120(2): 534-544.
7
Okumoto K, Saito T, Hattori E, et al. Differentiation of rat bone marrow cells cultured on artificial basement membrane containing extracellular matrix into a liver cell lineage. J Hepatol, 2005, 43(1): 110-116.
8
Wang YF, Nan X, Yu CZ, et al. Differentiation of bone marrow derived Thy-1+ beta2M- cells into liver cells in AA induced liver injury micro-environment. Zhonghua Gan Zang Bing Za Zhi, 2005, 13(4): 274-277.
9
Iimuro Y, Brenner DA. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res, 2008, 25(2): 249-258.
10
Ball SG, Shuttleworth AC, Kielty CM. Direct cell contact influences bone marrow mesenchymal stem cell fate. Int J Biochem Cell Biol, 2004, 36(4): 714-727.
11
Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells, 2007, 25(7): 1737-1745.
12
Gao J, Dennis JE, Muzic RF, et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs, 2001, 169(1): 12-20.
13
Fang B, Shi M, Liao L, et al. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation, 2004, 78(1): 83-88.
14
Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology, 2004, 126(4): 955-963.
15
Baba S, Fujii H, Hirose T, et al. Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol, 2004, 40(2): 255-260.
16
Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res, 2002, 62(13): 3603-3608.
17
Lee KD, Kuo TK, Whang-Peng J, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology, 2004, 40(6): 1275-1284.
18
Oyagi S, Hirose M, Kojima M, et al. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. J Hepatol, 2006, 44(4): 742-748.
19
Lee TH, Jawan B, Chou WY, et al. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med, 2006, 8(6): 764-772.
20
Iimuro Y, Fujimoto J. Strategy of gene therapy for liver cirrohosis and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg, 2003, 10(1): 45-47.
21
Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest, 2002, 109(10): 1291-1302.
22
Yamamoto N, Terai S, Ohata S, et al. A subpopulation of bone marrow cells depleted by a novel antibody, anti-Liv8, is useful for cell therapy to repair damaged liver. Biochem Biophys Res Commun, 2004, 313(4): 1110-1118.
23
Oe H, Kaido T, Mori A, et al. Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogas troenterology, 2005, 52(65): 1393-1397.
24
Hung SC, Lu CY, Shyue SK, et al. Lineage differentiation-associated loss of adenoviral susceptibility and Coxsackie-adenovirus receptor expression in human mesenchymal stem cells. Stem Cells, 2004, 22(7): 1321-1329.
25
Wang LS, Duan HF, Hu JW, et al. Treatment of CCl4 induced chronic liver injury with bone marrow mesenchymal stem cells overexpressing hepatocyte growth factor. Zhonghua Gan Zang Bing Za Zhi, 2005, 13(12): 934-936.
26
Skarpen E, Oksvold MP, Grosvik H, et al. Altered regulation of EGF receptor signaling following a partial hepatectomy. J Cell Physiol, 2005, 202(3): 707-716.
27
徐迎新, 王文杰, 宋旭华, 等. 骨髓间充质干细胞定向肝细胞样分化的研究. 中华实验外科杂志, 2004, 21(2):152-153.
28
何忠杰, 方驰华, 马俊勋, 等. 肝细胞生长因子与表皮细胞生长因子联合诱导大鼠骨髓间充质干细胞分化为类肝细胞. 解放军医学杂志, 2006, 31(5):446-449.
29
Lin N, Lin J, Bo L, et al. Differentiation of bone marrow-derived mesenchymal stem cells into hepatocyte-like cells in an alginate scaffold. Cell Prolif, 2010, 43(5): 427-434.
30
吴玉卓, 张玉婷, 毛小荣, 等. EGF和HGF体外诱导肝硬化患者骨髓间充质干细胞向肝细胞分化的实验研究. 第三军医大学学报, 2008, 30(16):1541-1544.
31
Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology, 2006, 130(6): 1807-1821.
32
Wang J, Bian C, Liao L, et al. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res, 2009, 39(12): 1219-1228.
33
Kim WH, Matsumoto K, Bessho K, et al. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol, 2005, 166(4): 1017-1028.
34
Parekkadan B, van Poll D, Megeed Z, et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun, 2007, 363(2): 247-252.
35
Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation, 2004, 109(12): 1543-1549.
36
Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol, 2004, 85(2): 47-64.
37
Hung KS, Lee TH, Chou WY, et al. Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Biochem Biophys Res Commun, 2005, 336(1): 324-331.
[1] 高建松, 陈晓晓, 冯婷, 包剑锋, 魏淑芳, 潘林. 基于超声瞬时弹性成像的多参数决策树模型评估慢性乙型肝炎患者肝纤维化等级[J]. 中华医学超声杂志(电子版), 2023, 20(09): 923-929.
[2] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[3] 罗丹, 孔为民, 陈姝宁, 赵小玲, 谢云凯. 子宫内膜异位症患者在位及异位内膜上皮细胞-间充质转化相关生物标志物的变化[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 530-539.
[4] 陈甜甜, 王晓东, 余海燕. 双胎妊娠合并Gitelman综合征孕妇的妊娠结局及文献复习[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 559-568.
[5] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[6] 黄威, 刘启, 陈流华, 滕茶香, 区喆建, 刘韩笑, 陈健聪, 张昆松. 新定义的可预测肝癌预后的焦亡相关lncRNA模型[J]. 中华普通外科学文献(电子版), 2023, 17(05): 357-365.
[7] 袁育韬, 邢金琳, 谢克飞, 殷凯. CT征象及BRAFV600E基因突变与甲状腺乳头状癌中央区淋巴结转移的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 611-614.
[8] 樊丽超, 郭瑾瑛, 陈鑫. 野生型RET与RET/PTC融合基因检测对甲状腺乳头状癌中央区淋巴结清扫的指导意义[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 631-635.
[9] 彭雨诗, 苗芸, 严紫嫣. 宏基因组高通量测序诊断肾移植术后华支睾吸虫感染一例[J]. 中华移植杂志(电子版), 2023, 17(05): 297-299.
[10] 刘恒, 侯宇川. 膀胱癌新型灌注药物的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 445-451.
[11] 许丁伟, 马江云, 李新成, 黄洁. Alagille综合征疑诊为先天性胆道闭锁一例并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 681-687.
[12] 陈安, 冯娟, 杨振宇, 杜锡林, 柏强善, 阴继凯, 臧莉, 鲁建国. 基于生物信息学分析CCN4在肝细胞癌中表达及其临床意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 702-707.
[13] 王飞飞, 王光林, 孟泽松, 李保坤, 曹龙飞, 张娟, 周超熙, 丁源一, 王贵英. 敲低IMPDH1对结肠癌SW480、HT29细胞生物功能的影响[J]. 中华临床医师杂志(电子版), 2023, 17(08): 884-890.
[14] 高红琴, 陈晨, 陆瑞科, 王小雨, 张敏, 李少华, 郝梨岚, 黄新程, 关凌耀, 张韵红. 外阴阴道假丝酵母菌病对女性阴道-宫颈菌群的影响研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 720-725.
[15] 张许平, 刘佳成, 张舸, 杜艳姣, 李韶, 商丹丹, 王浩, 李艳, 段智慧. CYP2C19基因多态性联合血栓弹力图指导大动脉粥样硬化型非致残性缺血性脑血管事件患者抗血小板治疗的效果[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 477-481.
阅读次数
全文


摘要